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In this issue of the Journal, Mitchell et al. (1) report that
lipid-lowering therapy (LLT) was associated with a 36%
relative risk reduction (RRR) in all-cause mortality in
patients with ischemic heart disease (IHD) enrolled in the
Antiarrhythmics Versus Implantable Defibrillator (AVID)
trial. This rivals the benefit observed for implantable car-
dioverter defibrillators (ICDs) over amiodarone therapy
(RRR 38%) (2) and is greater than the effect of LLT
observed in patients with IHD in the Scandinavian Simva-
statin Survival Study (4S) (RRR 30%) and in the Long-term
Intervention with Pravastatin in Ischemic Disease (LIPID)
trial (RRR 22%) (3,4). This striking effect could be
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dismissed for a number of reasons. The fact that LLT was
not randomized and outcome assessment was not a pre-
planned analysis raises the likelihood of a statistically
significant association due to chance or selection bias.
Another possibility is that the severity of disease and
comorbid conditions in AVID trial patients magnified the
mortality benefit of LLT. Moreover, any advantage of LLT
could be considered moot because application of current
guidelines for LLT mandate treatment of most if not all
patients with IHD similar to those enrolled in the AVID
study.
Although all-cause mortality is all-important, the finding
that LLT has antiarrhythmic activity would make LLT
distinctive if not unique among other available treatments.
No conventional antiarrhythmic drug has been shown
unequivocally to reduce mortality, with the possible excep-
tion of amiodarone, which has been shown to lower mor-
tality modestly (RRR 13%) (5). Beta-blockers dramatically
reduce all-cause and sudden death in heart failure and after
myocardial infarction (MI) (5) but were not associated with
a reduction in death or recurrent arrhythmia in patients
treated with ICDs or amiodarone in the AVID trial (6).
An effective, safe, well-tolerated antiarrhythmic therapy
could have substantial clinical impact. Implantable cardio-
verter defibrillators can prevent sudden cardiac death
(SCD), but patients with recurrent ventricular tachyar-
rhythmias (VTA) can experience debilitating symptoms due
to syncope, pain, and anxiety. Adverse psychological reac-
tions may occur in both patients and family members (7).
Although outcome variables differed, the 40% RRR in
recurrent VTA observed with LLT by Mitchell et al. (1) is
roughly comparable to the 44% reduction for first appropri-
ate ICD shock or death reported for sotalol in a placebo-
controlled, randomized trial in patients with ICDs (8).
Therefore, use of LLT could improve quality of life in
patients with ICDs. On a grander scale, these observations
hold out the possibility of a treatment that could help
control the worldwide epidemic of SCD.
Mechanisms. A plausible mechanism for LLT and re-
duced VTA would enhance the credibility of the statistical
association reported by Mitchell et al. (1). In addition,
identification of a mechanism would indicate if LLT could
benefit patients without IHD or patients with supraventric-
ular arrhythmias. Myocardial ischemia is a potent initiator
of VTA. By inhibiting luminal narrowing, hemostatic and
inflammatory processes, by restoring endothelial function,
or by a number of other mechanisms, LLT could reduce
episodes of ischemia. Pravastatin has been shown to reduce
transient ischemia in patients on optimal anti-anginal ther-
apy in a double-blind, randomized, controlled trial (9).
However, evidence for ischemia is rarely present in associ-
ation with VTA in patients with recurrent VTA as assessed
by symptoms or electrocardiographic changes before the
onset of recorded spontaneous sustained VTA (10). Ven-
tricular tachyarrhythmias can often be initiated by pro-
grammed electrical stimulation in the absence of ischemia,
but VTA are not reliably initiated with stress testing.
Evidence of stress-induced ischemia imaging does not
predict arrhythmic events, and revascularization does not
prevent recurrent arrhythmic events (11,12). The likelihood
that ischemia caused arrhythmias in the patients reported by
Mitchell et al. was reduced because patients with evidence
of an ischemic mechanism for their index arrhythmia were
excluded from the AVID trial (13). Also, among patients in
the AVID trial who died suddenly, evidence of ischemia was
detected in only 4 of 79 (14).
Despite the lack of evidence for ischemia in the genesis of
recurrent VTA, it has not been possible to exclude its
participation. Ischemia of a region critical to a reentrant
circuit could affect an area of myocardium too small to cause
symptoms, to produce electrocardiographic (ECG) changes,
to be detected by stress-imaging methods, or to be elimi-
nated with revascularization. Analyses of ECG records of
spontaneous VTA demonstrate that many if not most VTA
are initiated in the absence of an identifiable trigger such as
a premature ventricular complex or short-long-short se-
quence (15). Initiation of reentry in the absence of a
premature beat or pause indicates that other factors cause
sufficient perturbation of the circuit so that reentry occurs
spontaneously or so that reentry of the previous sinus beat is
facilitated. Determination of the role of ischemia is crucial
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Department of Cardiology, Marshfield Clinic, Marshfield, Wisconsin.
Journal of the American College of Cardiology Vol. 42, No. 1, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00497-2
because if LLT possesses an antiarrhythmic effect indepen-
dent of ischemia, it might benefit patients with nonischemic
arrhythmia mechanisms. At present, however, reduction of
ischemia can be neither accepted nor excluded as the
mechanism for the antiarrhythmic effects of LLT.
Increased sympathetic activity is likely to participate in
the spontaneous initiation of sustained VTA in some
patients prone to recurrent episodes (10). Sympathetic
activity can stimulate several processes that can be arrhyth-
mogenic including ischemia (16). Therefore, the report that
LLT and improves autonomic function indicates another
mechanism by which LLT could reduce VTA events (17).
Lipid-lowering therapy could exert antiarrhythmic effects
by altering ionic currents across the myocyte cell membrane.
Individual lipid-lowering drugs might interact directly with
ion channel proteins by mechanisms similar to conventional
antiarrhythmic drugs, but it is unlikely that the diverse
group of drugs that have lipid-lowering properties would
have a uniform effect on ion channel function. A more
plausible possibility is that LLT alters channel protein
function by changing the lipid environment of the cell or
organelle membranes. It was once assumed that the bilayer
phospholipid structure of membranes served only to sepa-
rate and electrically insulate individual cells and organelles
and to provide structural support for the membrane proteins
that were responsible for the regulation of transmembrane
functions. However, it was demonstrated several years ago
that the phospholipid composition of membranes was not
static but could change according to the dietary distribution
of fatty acids. Moreover, it was shown that membrane
functions can be perturbed by changes in dietary fatty acids
(18). Alterations in protein channel function mediated by a
change in cell membrane phospholipid composition has
been proposed to be the mechanism by which n-3 (also
called omega-3) polyunsaturated fatty acids (PUFA) reduce
the risk of sudden death (19). Recently, for instance, Honen
and Saint (20) showed that diets supplemented by lard,
canola oil, or fish oil altered duration of calcium sparks in rat
atrial myocytes. The investigators speculated that the
change in calcium kinetics observed with the fish-oil diet
reduces the propensity for the class of arrhythmias related to
“calcium overload.” A credible antiarrhythmic effect should
have a proarrhythmic counterpart. In other words, if a
change in membrane phospholipid composition can be
antiarrhythmic, an opposing change should be proarrhyth-
mic. This has been proposed as the mechanism by which
trans-fatty acids increase the risk of primary cardiac arrest
(21).
Recurrent VTA in patients with IHD are believed to
result, in part, from remodeling associated with progressive
electrophysiologic changes due to the formation of anatomic
barriers, regions of slow conduction, and prolonged and
heterogeneous repolarization. An MI often initiates the
process, but inflammation, ischemia, neuroendocrine stim-
ulation, and other factors continue for years. The impor-
tance of remodeling to the arrhythmogenic process in IHD
is suggested by the long delay between MI and the first
episode of VTA (5.7 years in the Electrophysiologic Study
Versus Electrocardiographic Monitoring trial) (15). Inhibi-
tion of remodeling has been demonstrated for some lipid-
lowering agents. Fluvastatin attenuated myocardial hyper-
trophy and fibrosis and reduced death due to heart failure
and arrhythmias in a mouse model of MI (22). In a
nonischemic model, simvastatin resulted in improvement of
cardiac function in association with regression of hypertro-
phy and fibrosis in rabbits with hypertrophic cardiomyopa-
thy (23). Probucol, a drug that lowers lipids by a mechanism
different from that of pravastatin and simvastatin, inhibited
remodeling and prevented worsening left ventricular func-
tion in a nonischemic canine model of remodeling and heart
failure produced by rapid pacing (24). In each of these
studies the observed effects on cardiac remodeling appeared
to be independent of lipid-lowering.
Previous studies. Reduction in SCD is expected of any
therapy that reduces the incidence and progression of IHD.
The 4S investigators enrolled patients with IHD and high
cholesterol levels and followed them for a mean of 5.4 years
(3). Simvastatin treatment reduced all-cause and IHD
mortality by 30% and 42%, respectively. Instantaneous
deaths in the absence of confirmed MI were less common in
the statin group than in the placebo group (29 vs. 39
patients) as were unwitnessed deaths (13 vs. 23). The only
cardiac arrest occurred in a patient treated with simvastatin.
Crude all-cause, IHD, and sudden (instantaneous) death
rates (calculated from the tabulated data) were 11.5%, 8.5%,
and 1.8% in the placebo group and 8.2%, 5.0%, and 1.3% in
the simvastatin group, respectively. The point estimate of
crude reduction in sudden death was 26%. A reduction of
SCD that is proportional to the reduction in IHD deaths is
anticipated for an intervention that affects SCD and non-
sudden deaths equally. Instead, the effect of LLT on SCD
was less than the effect on all IHD deaths (26% vs. 42%). A
related observation is that the percentage of SCD with
respect to IHD deaths was lower in the placebo group (21%)
than in the simvastatin group (26%). The LIPID trial
included patients with IHD and a broad range of cholesterol
levels (4). A 24% RRR for IHD deaths was observed. The
SCD mortality (defined differently than in 4S) in the
LIPID trial was 4.7% (n  211) in the placebo group and
4.0% in the treatment group (n  182). This represents a
crude reduction of SCD of only 14%. All-cause and IHD
mortality in the placebo group was 14.1% (n  633) and
8.3% (n  373), respectively, and 11.0% (n  498) and
6.4% (n 287), respectively in the LLT group. As observed
in the 4S, the percentage of SCD to all IHD deaths in the
LIPID study was smaller in the placebo group (57%) than in
the treatment group (63%). In contrast, the Gruppo Italiano
per lo Studio della Sopravvivenza nell’Infarto Miocardico
(GISSI)-Prevenzione investigators reported that dietary
supplementation with n-3 PUFA reduced all-cause mortal-
ity by 20%, cardiovascular deaths by 30%, and SCD by 45%
(25). Thus, although LLT clearly reduces SCD, the effect
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does not appear to be selective. None of the major random-
ized trials of LLT have reported a statistically significant
effect on VTA or SCD incidence, whereas the effects of n-3
PUFA appear relatively consistent (26). On the other hand,
none of the trials of LLT had adequate statistical power to
evaluate SCD as an end point. Therefore, the effect of LLT
on SCD remains unresolved.
The absence of a preferential effect of LLT on primary
prevention of SCD should not be overemphasized in the
assessment of a possible salutary effect in patients with
recurrent VTA. In a retrospective study of patients compa-
rable to those enrolled in the AVID trial, De Sutter et al.
(27) analyzed 78 patients with ICDs and IHD. Patients
with VTA in the setting of acute MI were excluded, as were
patients in whom VTA could not be induced at electro-
physiologic study after revascularization. During a mean
follow-up of 490 319 days, the 27 patients receiving LLT
demonstrated a lower incidence of VTA recurrence (22%)
compared with controls (57%, p  0.004). A multivariate
analysis demonstrated that use of LLT was an independent
predictor of freedom from VTA recurrence.
Uncertainties. The drugs used for LLT have different
mechanisms of actions, potencies, and effects beyond lipid-
lowering. In the study of Mitchell et al., LLT ascertainment
was based on the response to a yes/no question on hospital
discharge and follow-up forms. The agent administered for
LLT was not known for the majority of patients. Detailed
information from a sample of 237 patients (23% of the
1,016 enrolled AVID patients) showed that 26% of the
patients received LLT, 79% of whom received statins, 19%
fibric acid derivatives, and 3% bile acid resins. This raises
the possibility that the observed beneficial effects were due
to a single class of drugs (i.e., statins). De Sutter et al. (27),
however, did not report a differential effect of statins (used
in 59% of the LLT patients) compared with those receiving
fibrates (41%).
The temporal relationship between the initiation of LLT
and the outcome variables also raises challenging questions
about the mechanisms. Only 20% of the LLT patients in
the ICD group studied by Mitchell et al. were started within
six months of the index hospitalization. The remaining 80%
were receiving LLT before, during, and after the index
VTA event. This pattern was also observed in the report of
De Sutter et al. (27) in which 89% of the treated patients
were receiving LLT at the time of presentation. Therefore,
LLT did not prevent the index VTA event in either study.
It is not known if LLT begun after the index VTA will
provide the same protective effect. Neither study definitely
supports nor excludes an immediate-type effect similar to
conventional antiarrhythmic drugs, which are believed to
exert their effects only in the presence of adequate concen-
trations at the effector sites. Conventional antiarrhythmic
drugs may reduce the frequency of arrhythmia recurrence
but rarely provide full protection (28). However, the ob-
served temporal relationship is also compatible with a
long-term effect. It is conceivable that LLT therapy exerted
salutary effects months or years before the index event by
inhibition of remodeling or improving myocardial perfu-
sion. Although the index VTA was not prevented, it is
possible that the frequency of subsequent events was re-
duced sufficiently to result in a favorable outcome in patients
receiving LLT.
Lipid levels were not measured in the AVID trial so it is
not possible to determine to what extent lipid-lowering was
achieved and how levels were related to arrhythmia inhibi-
tion. A correlation between lipid lowering and the antiar-
rhythmic effects of LLT would not only strengthen the
postulated relationship but also would help to delineate the
mechanisms. In the study of De Sutter et al. (27), total
cholesterol (TC) and low density lipid-cholesterol
(LDL-C) were not significantly different between the LLT
group and the non-LLT group at the time of index hospital
discharge (TC in LLT group 192  47 mg/dl, non-LLT
group 215  50 mg/dl, p  0.119; LDL-C in LLT group
122  47 mg/dl, non-LLT group 132  37 mg/dl, p 
0.419) despite the fact that 89% of the LLT patients were
already receiving LLT. Both TC and LDL-C levels rose
significantly in both groups during the follow-up period
(end of follow-up TC in the LLT group: 213  25 mg/dl,
p 0.005; non-LLT group 257 47 mg/dl, p 0.01; end
of follow-up LDL-C in the LLT group 139  23 mg/dl,
p  0.016; non-LLT: 172  40 mg/dl, p  0.01 [p values
refer to comparison of beginning and end of follow-up
values]). Thus, the observed differences in VTA events
occurred as lipid levels rose in both groups. The rise in the
non-LLT group was greater than that in the LLT group so
that cholesterol levels at the end of the observation period
were significantly greater in the non-LLT patients for both
total cholesterol (p  0.004) and LDL-C (p  0.015). It
cannot be assumed that cholesterol levels responded differ-
ently in the AVID trial. These observations provide no
reassurance that lipid-lowering was responsible for the
beneficial effects of LLT in either investigation. On the
other hand, measurement of cholesterol levels may not fully
reflect alterations in the distribution of lipids during LLT.
In addition, the observed antiarrhythmic effects of LLT may
be unrelated to lipid lowering.
Safety of LLT. The patients studied by Mitchell et al. (1)
had poor ventricular function (mean left ventricular ejection
fraction 0.31), a high prevalence of congestive heart failure
(45%), and several comorbid conditions, such as diabetes
(26%) and chronic lung (16%) and renal (8%) disease. These
characteristics distinguish the patients analyzed by Mitchell
et al. from those in most LLT trials. Subjects were excluded
from the 4S if they had an MI within six months, require-
ment for antiarrhythmic therapy, congestive heart failure,
persistent atrial fibrillation, cardiomegaly, valvular heart
disease, etc. (3). The LIPID trial excluded patients with MI
within less than three months, “a clinically significant
medical or surgical event within three months, cardiac
failure, renal or hepatic disease” (4). Lipid-lowering therapy
has an excellent safety record in trials of patients at low risk.
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However, the safety of LLT in high-risk individuals has
been challenged by a post hoc observational analysis of the
Sibrafiban vs. Aspirin to Yield Maximum Protection From
Ischemic Heart Events Post-acute Coronary Syndromes
(SYMPHONY) trials. The analysis showed that LLT
therapy in patients who presented with ACS with levels of
cholesterol below treatment guidelines was associated with
higher risks of death and MI (29). Moreover, many of the
patients analyzed by Mitchell et al. (1) received amiodarone,
which interacts with several lipid-lowering drugs and could
exacerbate or inhibit electrophysiologic changes caused by
LLT. Therefore, it is noteworthy that neither Mitchell et al.
(1) nor De Sutter et al. (27) reported any adverse effects of
LLT.
Conclusions. The study of Mitchell et al. raises the in-
triguing possibility that LLT inhibits VTA recurrence in
patients with IHD and AVID trial enrollment criteria (i.e.,
patients who present with sustained VTA in association
with cardiac arrest, syncope, or left ventricular ejection
fraction of 0.40 and symptoms of hemodynamic compro-
mise in the absence of a transient or reversible cause) (13).
Because of its post hoc, nonrandomized design, the results
must be considered preliminary. Additional research is
needed to address the potential mechanisms of the antiar-
rhythmic effects and, in particular, the link between lipid-
lowering and antiarrhythmic actions. Clinical trials are
needed to verify the antiarrhythmic effects. However, trials
will be complicated by existing guidelines that mandate
LLT in most patients who would be candidates for inves-
tigation. However, current guidelines are not based on
trial-based evidence for this population of patients in whom
neither the safety nor benefit has been adequately evaluated.
Furthermore, current guidelines specify lipid-lowering tar-
gets, whereas the antiarrhythmic benefits may be indepen-
dent of this effect and could differ significantly among
lipid-lowering agents. The Cholesterol Lowering and Ar-
rhythmias Recurrences After Internal Defibrillator Implan-
tation (CLARIDI) trial will evaluate the effect of atorvasta-
tin versus placebo in patients with ICD, IHD, and normal
or borderline cholesterol levels (30). Arrhythmia outcome
variables should be evaluated in future trials of LLT that
include patients at high risk for both atrial and ventricular
arrhythmias (23). In this regard, the study of Mitchell et al.
has not only raised the level of awareness of this important
potential benefit of LLT but also has provided important
reassurance that LLT is safe in this population of patients
with severely depressed myocardial function and numerous
comorbid conditions.
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